<DOC>
	<DOCNO>NCT02238197</DOCNO>
	<brief_summary>To obtain information tolerability efficacy Atrovent® 500µg/2ml inhalation solution treatment Chronic Obstructive Pulmonary Disease condition daily practice</brief_summary>
	<brief_title>Postmarketing Surveillance Study Atrovent® Inhalation Solution Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Patients gender , old 40 year , suffer chronic obstructive Pulmonary disease Only patient treat Atrovent® within last year consider inclusion Contraindication list instruction use/summary product characteristic Atrovent® 500µg/2ml Inhalation Solution Patients exhibit adverse drug reaction</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>